The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment

Area of Science:

• Oncology
• Immunology
• Endocrinology

Background:

• Diabetes mellitus and cancer frequently co-occur, necessitating concurrent treatment with antidiabetic and antitumor drugs.
• Immunotherapy, particularly immune checkpoint inhibitors like anti-PD1, has revolutionized cancer treatment.
• The interaction between antidiabetic medications and immunotherapy efficacy remains largely unexplored.

Purpose of the Study:

• To investigate the impact of six common antidiabetic drugs on the efficacy of anti-PD1 immunotherapy in preclinical cancer models.
• To identify specific antidiabetic agents that may enhance or impede anti-PD1 therapy.

Main Methods:

• Utilized syngeneic mouse models for colon cancer and melanoma.
• Administered six antidiabetic drugs (acarbose, sitagliptin, metformin, glimepiride, pioglitazone, insulin) in combination with anti-PD1 therapy.
• Evaluated the effects on tumor growth inhibition and anti-PD1 therapeutic response.

Main Results:

• Acarbose and sitagliptin demonstrated synergistic effects, enhancing anti-PD1-mediated tumor inhibition.
• Metformin showed no significant impact on anti-PD1 efficacy.
• Glimepiride, pioglitazone, and insulin attenuated the therapeutic effects of anti-PD1 therapy.

Conclusions:

• The choice of antidiabetic medication is critical for cancer patients undergoing anti-PD1 immunotherapy.
• Acarbose shows promise as an adjuvant therapy, significantly enhancing anti-PD1 efficacy and inhibiting tumor growth.
• Further clinical investigation is warranted to validate these findings and guide clinical practice.